Moderna, FDA reach compromise to accelerate approval of mRNA flu vaccine

Flu Shot

The dispute centered around the pharmaceutical company's request for the shot to be approved for those aged 65 and over, a demographic the FDA argued was not properly represented in a 40,000-person clinical study. The company has agreed to perform additional research after the shot goes to market, having appeased regulators with safety data.